索非布韦/韦帕他韦对合并感染丙型肝炎病毒（HCV）基因型 3b 的艾滋病患者的疗效降低

IF 2.1 4区医学 Q3 VIROLOGY

Future Virology Pub Date : 2024-02-28 DOI:10.2217/fvl-2023-0112

Jingdi Zhou, Fada Wang, Lanzhi Li, Jing-Yu Li, En-Qiang Chen

{"title":"索非布韦/韦帕他韦对合并感染丙型肝炎病毒（HCV）基因型 3b 的艾滋病患者的疗效降低","authors":"Jingdi Zhou, Fada Wang, Lanzhi Li, Jing-Yu Li, En-Qiang Chen","doi":"10.2217/fvl-2023-0112","DOIUrl":null,"url":null,"abstract":"Aim: To retrospectively assess the efficacy and safety of sofosbuvir/velpatasvir for hepatitis C virus (HCV) genotype 3b in HIV-infected patients receiving antiretroviral therapy (ART) treatment of lamivudine/tenofovir disoproxil fumarate/efavirenz. Methods: The primary end point of HCV treatment was estimated by sustained virologic response 12 weeks after treatment (SVR12). Results: Sixteen subjects who were followed up for 48 weeks after treatment were included. The SVR12 and SVR48 were 87.5% (95% CI: 60.4–97.8%) and 81.3% (95% CI: 53.7–95.0%), respectively. One patient experienced persistent low-level viremia of HIV after 12 weeks of treatment. Conclusion: Twelve weeks of SOF/VEL is safe but has limited efficacy for HCV GT3b in HIV-infected patients receiving ART regimen including efavirenz, especially among patients with baseline HCV RNA≥6.0 log10 IU/ml.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Decreased efficacy of sofosbuvir/velpatasvir in HIV patients coinfected with HCV genotype 3b\",\"authors\":\"Jingdi Zhou, Fada Wang, Lanzhi Li, Jing-Yu Li, En-Qiang Chen\",\"doi\":\"10.2217/fvl-2023-0112\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: To retrospectively assess the efficacy and safety of sofosbuvir/velpatasvir for hepatitis C virus (HCV) genotype 3b in HIV-infected patients receiving antiretroviral therapy (ART) treatment of lamivudine/tenofovir disoproxil fumarate/efavirenz. Methods: The primary end point of HCV treatment was estimated by sustained virologic response 12 weeks after treatment (SVR12). Results: Sixteen subjects who were followed up for 48 weeks after treatment were included. The SVR12 and SVR48 were 87.5% (95% CI: 60.4–97.8%) and 81.3% (95% CI: 53.7–95.0%), respectively. One patient experienced persistent low-level viremia of HIV after 12 weeks of treatment. Conclusion: Twelve weeks of SOF/VEL is safe but has limited efficacy for HCV GT3b in HIV-infected patients receiving ART regimen including efavirenz, especially among patients with baseline HCV RNA≥6.0 log10 IU/ml.\",\"PeriodicalId\":12505,\"journal\":{\"name\":\"Future Virology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Virology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/fvl-2023-0112\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"VIROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Virology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fvl-2023-0112","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：回顾性评估索非布韦/韦帕他韦治疗接受拉米夫定/替诺福韦二吡呋酯/依非韦伦抗逆转录病毒疗法（ART）治疗的丙型肝炎病毒（HCV）基因型3b感染者的疗效和安全性。治疗方法HCV治疗的主要终点是治疗12周后的持续病毒学应答（SVR12）。结果16名受试者在治疗后接受了48周的随访。SVR12和SVR48分别为87.5%（95% CI：60.4-97.8%）和81.3%（95% CI：53.7-95.0%）。一名患者在治疗 12 周后出现持续的低水平 HIV 病毒血症。结论对于接受包括依非韦伦在内的抗逆转录病毒疗法的HIV感染者，尤其是基线HCV RNA≥6.0 log10 IU/ml的患者，12周的SOF/VEL治疗是安全的，但对HCV GT3b的疗效有限。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Decreased efficacy of sofosbuvir/velpatasvir in HIV patients coinfected with HCV genotype 3b

Aim: To retrospectively assess the efficacy and safety of sofosbuvir/velpatasvir for hepatitis C virus (HCV) genotype 3b in HIV-infected patients receiving antiretroviral therapy (ART) treatment of lamivudine/tenofovir disoproxil fumarate/efavirenz. Methods: The primary end point of HCV treatment was estimated by sustained virologic response 12 weeks after treatment (SVR12). Results: Sixteen subjects who were followed up for 48 weeks after treatment were included. The SVR12 and SVR48 were 87.5% (95% CI: 60.4–97.8%) and 81.3% (95% CI: 53.7–95.0%), respectively. One patient experienced persistent low-level viremia of HIV after 12 weeks of treatment. Conclusion: Twelve weeks of SOF/VEL is safe but has limited efficacy for HCV GT3b in HIV-infected patients receiving ART regimen including efavirenz, especially among patients with baseline HCV RNA≥6.0 log10 IU/ml.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Virology 医学-病毒学

CiteScore

4.00

自引率

3.20%

发文量

审稿时长

6-12 weeks

期刊介绍： Future Virology is a peer-reviewed journal that delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this ever-expanding area of research. It is an interdisciplinary forum for all scientists working in the field today.